AIM
CTKB icon

Aigen Investment Management’s Cytek Biosciences CTKB Stock Holding History

Aigen Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,730
Closed -$50.1K – 851
2025
Q2 		$50.1K Buy
+14,730
New +$49.1K 0.01% 745
2023
Q1 		– Sell
-14,102
Closed -$144K – 661
2022
Q4 		$144K Buy
+14,102
New +$190K 0.02% 480

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's CTKB Position: Q3 2025 in Review

Aigen Investment Management sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 14,730 shares — an estimated $50.1K sold.

Aigen Investment Management first reported a position in CTKB in Q4 2022 and held it in 2 quarters. The position peaked at $144K in Q4 2022. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • Aigen Investment Management reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • Aigen Investment Management sold 14,730 Cytek Biosciences shares in Q3 2025, an estimated $50.1K.
  • Aigen Investment Management first reported a position in Cytek Biosciences in Q4 2022 and held it in 2 quarters.
  • Aigen Investment Management's Cytek Biosciences position peaked at $144K in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Aigen Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.